Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philips Acquires Shanghai Apex, Targets Low-End Ultrasound Market In Wake Of China Healthcare Reform

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Amsterdam-based Royal Philips Electronics has acquired Shanghai Apex, an ultrasound transducer provider in China, to expand Philips' low-end ultrasound product line to take advantage of the growing device market expected from China's ongoing healthcare reforms, the company announced July 28

You may also be interested in...



Lower-Tier Hospitals Will See More Medical Device Growth In 2013: Citi Hospital Survey

Spending on new medical equipment by top-tier hospitals in China is expected to ease in 2013, but still show double-digit growth with multinationals like General Electric competing with domestic firms led by Mindray Medical.

SFDA Requires Chinese Labeling For Imported Medical Devices

New labeling could impact a range of multinational diagnostic and device companies, particularly those that import finished products.

Facing Tougher Competition At Home, China's Mindray Should Target Global Mid- To High-end Market, Analysts Say

Facing a new round of marketing campaigns from international device makers targeting China's low- to mid-end hospital markets, Shenzhen based Mindray Medical will be better off focusing instead on mid- to high-end global markets to stay competitive, analysts say

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel